Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/9/2017
SIETES contiene 92006 citas

 
 
 1 a 20 de 327 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, Smeeth L. Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. BMJ 2017;358:j3334. [Ref.ID 101997]
2. Cita con resumen
Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]
3. Cita con resumen
Rosenberg HG, Shnier A. Regulatory data are hidden in plain sight. BMJ 2017;358:j3437. [Ref.ID 101980]
4. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
5. Cita con resumen
Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings—A cross-sectional study. JAMA Intern Med 2017;177:1038-40. [Ref.ID 101664]
6. Cita con resumen
7. Cita con resumen
Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]
8. Cita con resumen
Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:28 de junio. [Ref.ID 101657]
10. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
11. Cita con resumen
Anónimo. UK’s NICE recommends ibrutinib after discount. DIA Daily 2016:2. [Ref.ID 100979]
13. Cita con resumen
Anónimo. EMA releases clinical trial data in transparency effort. DIA Daily 2016:1. [Ref.ID 100849]
16.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
17.Enlace a cita original Cita con resumen
Anónimo. La falsa transparencia y el lavado de cara de la industria farmacéutica. NoGracias 2016:1 de julio. [Ref.ID 100507]
18. Cita con resumen
Anónimo. NICE endorses bosutinib for treatment of myeloid leukemia. DIA Daily 2016:3. [Ref.ID 100484]
19. Cita con resumen
Anónimo. EU ombudsman: EMA should release adalimumab data. DIA Daily 2016:1. [Ref.ID 100412]
20. Cita con resumen
Garattini S. The European Medicines Agency is still too close to industry. BMJ 2016;353:i2412. [Ref.ID 100360]
Seleccionar todas
 
 1 a 20 de 327 siguiente >>